Compare Snowflake Inc (SNOW) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs Tango Therapeutics Inc. — how do they compare? Snowflake Inc trades at $329.98 (market cap $126.22B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Snowflake Inc is far larger — about 33.7× Tango Therapeutics Inc.'s market cap, and Snowflake Inc is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Snowflake Inc for 53 Days and Tango Therapeutics Inc. for 0 Days on average.
| SNOW | TNGX | |
|---|---|---|
Market Cap | $126.22B | $3.75B |
Volume | 4,112,138 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $368.89 | $32.90 |
52-Week Low | $121.11 | $7.50 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $126.64B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snowflake (SNOW) trades at $335.08, down 7.02% amid market volatility, but maintains strong analyst support with 81% buy ratings and a $418.03 consensus target. The company shows robust revenue growth, reaching $3.63 billion in 2025, though it remains unprofitable with a -20.07% net margin. Recent technical indicators are bullish on moving averages, while oscillators remain neutral. Key developments include a $3.75 billion convertible note offering and expanded partnerships with UiPath.
Outlook remains positive given strong revenue trajectory and analyst confidence, but risks include persistent losses, high valuation multiples (P/S 22.66), and competitive pressures. The stock offers growth potential if profitability improves, yet investors must weigh execution risks against long-term AI data cloud opportunities.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
